Business
Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare Conference
Progresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023 Presents New Preclinical In Vivo Data
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nProgresses Phase 2 SPRINT Trial of EDP-235, an Oral, 3CL Protease Inhibitor for COVID-19, With Data Expected in 1H 2023\n\n\nPresents New Preclinical In Vivo Data Demonstrating EDP-235’s Efficacy and Prevention of COVID-19 Transmission\n\n\nExpands Robust COVID-19 Antiviral Portfolio With a New Research Program Developing SARS-CoV-2 Papain-Like Protease Inhibitors\n\n\nIntroduces New Research Program Targeting Human Metapneumovirus (hMPV) and Respiratory Syncytial Virus (RSV) with a Single Agent; Clinical Candidate Selection Targeted for 4Q 2023\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., Enanta’s President and Chief Executive Officer, will provide an update across its pipeline of virology programs and plans for 2023 during Enanta’s presentation at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023 at 3:00 p.m. PT.\n\n“Building upon the advancements in both our COVID-19 and RSV programs during this past year, we enter 2023 poised for success by expanding our pipeline and executing against several important milestones to pursue our goal of developing curative therapies for viral infections,” said Jay R. Luly, President & Chief Executive Officer at Enanta Pharmaceuticals. “In particular, we are encouraged that we are on track to announce data in the first half of 2023 from SPRINT, our ongoing Phase 2 study of EDP-235, an oral, 3CL protease inhibitor specifically designed for the treatment of COVID-19. We are also excited to present new preclinical in vivo data demonstrating EDP-235’s robust antiviral treatment effect and its ability to prevent the transmission of COVID-19 in a ferret model. We are also enthusiastic about expanding our COVID-19 treatment program by developing SARS-CoV-2 Papain-Like Protease (PLpro) inhibitors. We believe that having multiple mechanisms to treat COVID-19, either alone or in combination, will allow us to bring best-in-class options to market for a range of patients suffering from this debilitating and deadly virus. In RSV, we continue to expect top-line data from the Phase 1 study of EDP-323, our L-protein inhibitor, in the first half of 2023. Additionally, we are pleased to build out...